{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:43:47Z","timestamp":1789145027199,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.vaccine.2024.04.016","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T08:52:22Z","timestamp":1712825542000},"page":"3239-3246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65\u00a0years-and-above in Switzerland"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4519-2857","authenticated-orcid":false,"given":"Kwame","family":"Owusu-Edusei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7276-9706","authenticated-orcid":false,"given":"Andrea","family":"Favre-Bulle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5225-6874","authenticated-orcid":false,"given":"Eleana","family":"Tsoumani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mutschler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Cossrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.04.016_b0005","doi-asserted-by":"crossref","unstructured":"Habib M, Porter BD, Satzke C. Capsular serotyping of Streptococcus pneumoniae using the Quellung reaction. Journal of visualized experiments : JoVE. Feb 24 2014;(84):e51208. 10.3791\/51208.","DOI":"10.3791\/51208-v"},{"key":"10.1016\/j.vaccine.2024.04.016_b0010","unstructured":"Centers for Disease Control and Prevention. Pneumococcal disease (Streptococcus pneumoniae). CDC. Accessed May, 2019. https:\/\/wwwnc.cdc.gov\/travel\/diseases\/pneumococcal-disease-streptococcus-pneumoniae."},{"key":"10.1016\/j.vaccine.2024.04.016_b0015","unstructured":"Centers for Disease Control and Prevention. Chapter 11: Pneumococcal, manual for the surveillance of vaccine-preventable diseases. CDC. Accessed May, 2023. https:\/\/www.cdc.gov\/vaccines\/pubs\/surv-manual\/chpt11-pneumo.html."},{"issue":"36","key":"10.1016\/j.vaccine.2024.04.016_b0020","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1016\/j.vaccine.2009.05.061","article-title":"Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions","volume":"27","author":"Ogilvie","year":"2009","journal-title":"Vaccine"},{"issue":"9136","key":"10.1016\/j.vaccine.2024.04.016_b0025","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0140-6736(98)02239-9","article-title":"Community-acquired pneumonia","volume":"352","author":"Brown","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2024.04.016_b0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejim.2007.03.015","article-title":"A comparative study of bacteremic and non-bacteremic pneumococcal pneumonia","volume":"19","author":"Jover","year":"2008","journal-title":"Eur J Intern Med"},{"issue":"10","key":"10.1016\/j.vaccine.2024.04.016_b0035","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1080\/21645515.2018.1475811","article-title":"Distribution of 13-valent pneumococcal conjugate vaccine serotype streptococcus pneumoniae in adults 50 Years and older presenting with community-acquired pneumonia in Israel","volume":"14","author":"Regev-Yochay","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"10.1016\/j.vaccine.2024.04.016_b0040","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vaccine.2024.04.016_b0045","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/cid\/cix549","article-title":"Evolving understanding of the causes of pneumonia in adults, with special attention to the role of pneumococcus","volume":"65","author":"Musher","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.04.016_b0050","unstructured":"WHO Stategic Advisory Group of Experts. Pneumococcal Vaccination of Older Adults: Report of the SAGE Working Group on Pneumococcal Vaccines. 2020."},{"key":"10.1016\/j.vaccine.2024.04.016_b0055","unstructured":"Bundesamt f\u00fcr Gesundheit (BAG). Invasive Pneumokokkenerkrankungen 2013\u20132017. Accessed February 22, 2024. https:\/\/www.bag.admin.ch\/dam\/bag\/de\/dokumente\/mt\/infektionskrankheiten\/pneumokokken-erkrankungen\/BAG_Bull_invasive-pneumokokken-2013-2017.pdf.download.pdf\/BAS_190107_BAG%20Bulletin_03_2019_DE_Pneumokokken.pdf."},{"issue":"10","key":"10.1016\/j.vaccine.2024.04.016_b0060","doi-asserted-by":"crossref","first-page":"e0186903","DOI":"10.1371\/journal.pone.0186903","article-title":"The full benefits of adult pneumococcal vaccination: a systematic review","volume":"12","author":"Cafiero-Fonseca","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.04.016_b0065","doi-asserted-by":"crossref","unstructured":"Farrar JL, Childs L, Ouattara M, et al. Systematic Review and Meta-Analysis of the Efficacy and Effectiveness of Pneumococcal Vaccines in Adults. Pathogens. May 19 2023;12(5)ARTN 732 10.3390\/pathogens12050732.","DOI":"10.3390\/pathogens12050732"},{"key":"10.1016\/j.vaccine.2024.04.016_b0070","unstructured":"The Food and Drug Administration. Pneumococcal 15-valent Conjugate Vaccine (Vaxneuvance). FDA. Accessed May, 2023. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/vaxneuvance."},{"key":"10.1016\/j.vaccine.2024.04.016_b0075","unstructured":"Bundesamt f\u00fcr Gesundheit (BAG) und Eidgen\u00f6ssische Kommission f\u00fcr Impffragen (EKIF). Pneumokokkenimpfung: Empfehlungen zur Verhinderung von invasiven Pneumokokkenerkrankungen bei Risikogruppen. Accessed June 20, 2023. https:\/\/www.bag.admin.ch\/dam\/bag\/de\/dokumente\/mt\/i-und-b\/richtlinien-empfehlungen\/empfehlungen-risikogruppen-isikosituationen\/empfehlung-verhinderunginvasive-pneumokokkenerkrankung-risikogruppen.pdf\/bu-8-2014-pneumokokken-risikogruppen.pdf."},{"key":"10.1016\/j.vaccine.2024.04.016_b0080","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fmed.2019.00286","article-title":"Influence of older age and other risk factors on pneumonia hospitalization in Switzerland in the pneumococcal vaccine era","volume":"6","author":"Albrich","year":"2019","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"10.1016\/j.vaccine.2024.04.016_b0085","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1080\/14760584.2022.2046468","article-title":"Cost-effectiveness of the 15-valent pneumococcal conjugate vaccine for high-risk adults in Switzerland","volume":"21","author":"Deb","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2024.04.016_b0090","unstructured":"Owusu-Edusei K, Deb A, Johnson KD. Estimates of the Health and Economic Burden of Pneumococcal Infections Attributable to the 15-Valent Pneumococcal Conjugate Vaccine Serotypes in the USA (Jan, 10.1007\/s40121-022-00588-x, 2022). Infectious Diseases and Therapy. Mar 6 2022;10.1007\/s40121-022-00613-z."},{"issue":"28","key":"10.1016\/j.vaccine.2024.04.016_b0095","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1016\/j.vaccine.2012.04.028","article-title":"Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland","volume":"30","author":"Blank","year":"2012","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.vaccine.2024.04.016_b0100","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1016\/S0264-410X(03)00193-2","article-title":"Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland","volume":"21","author":"Ess","year":"2003","journal-title":"Vaccine"},{"issue":"27\u201330","key":"10.1016\/j.vaccine.2024.04.016_b0105","first-page":"4145","article-title":"Invasive meningococcal and pneumococcal disease in Switzerland: cost-utility analysis of different vaccine strategies","volume":"21","author":"Ruedin","year":"2003","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2024.04.016_b0110","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/14760584.2021.1994858","article-title":"Matching-adjusted indirect comparison of pneumococcal vaccines V114 and PCV20","volume":"21","author":"Mt-Isa","year":"2022","journal-title":"Expert Rev Vaccines"},{"issue":"suppl_1","key":"10.1016\/j.vaccine.2024.04.016_b0115","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1093\/ofid\/ofy209.021","article-title":"151. evaluation of pneumococcal vaccine effectiveness against invasive pneumococcal disease among US medicare beneficiaries \u226565 Years old","volume":"5","author":"Pilishvili","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2024.04.016_b0120","doi-asserted-by":"crossref","first-page":"847","DOI":"10.4161\/hv.9898","article-title":"Economic evaluation of varicella vaccination in swiss children and adolescents","volume":"5","author":"Banz","year":"2009","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2024.04.016_b0125","unstructured":"Federal Office of Statistics. Bruttoinlandprodukt pro Einwohner - 1991-2019 (Bruttoinlandprodukt pro Einwohner - 1991-2019). Accessed May 10, 2023. https:\/\/www.bfs.admin.ch\/bfs\/de\/home\/statistiken\/querschnittsthemen\/wohlfahrtsmessung\/alle-indikatoren\/wirtschaft\/reales-bip-pro-kopf.assetdetail.14347461.html."},{"key":"10.1016\/j.vaccine.2024.04.016_b0130","first-page":"1","article-title":"Cost effectiveness of elderly pneumococcal vaccination in presence of higher-valent pneumococcal conjugate childhood vaccination: systematic literature review with focus on methods and assumptions","author":"Treskova","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"10.1016\/j.vaccine.2024.04.016_b0135","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s11606-016-3651-0","article-title":"Incremental cost-effectiveness of 13-valent pneumococcal conjugate vaccine for adults age 50 years and older in the United States","volume":"31","author":"Stoecker","year":"2016","journal-title":"J Gen Intern Med"},{"issue":"10","key":"10.1016\/j.vaccine.2024.04.016_b0140","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.vaccine.2018.01.052","article-title":"The role of timeliness in the cost-effectiveness of older adult vaccination: a case study of pneumococcal conjugate vaccine in Australia","volume":"36","author":"Chen","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.04.016_b0145","unstructured":"Stoecker C. Economic Assessment of PCV20 for Adults Vaccinated with PCV13: Presented at ACIP, October 19, 2022. 2022. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-06\/01-Pneumococcal-Poehling-508.pdf."},{"key":"10.1016\/j.vaccine.2024.04.016_b0150","unstructured":"Stoecker C. Economic Assessment of PCV15 & PCV20: Presentation to the ACIP June 25, 2021. 2021. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-06\/01-Pneumococcal-Poehling-508.pdf."},{"key":"10.1016\/j.vaccine.2024.04.016_b0155","unstructured":"Eidgen\u00f6ssisches Departement des Innern EDI Bundesamt f\u00fcr Gesundheit (BAG). Vaxneuvance. Accessed Mai 2, 2023. http:\/\/www.spezialitaetenliste.ch\/."},{"key":"10.1016\/j.vaccine.2024.04.016_b0160","unstructured":"TARMED. Accessed July 23, 2020. https:\/\/www.tarmed-browser.ch\/de."},{"issue":"7","key":"10.1016\/j.vaccine.2024.04.016_b0165","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.vaccine.2019.12.029","article-title":"Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program","volume":"38","author":"Stoecker","year":"2020","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2024.04.016_b0170","first-page":"43","article-title":"Parents' utilities for outcomes of occult bacteremia","volume":"154","author":"Bennett","year":"2000","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"7\u20138","key":"10.1016\/j.vaccine.2024.04.016_b0175","first-page":"572","article-title":"Quel suivi \u00e0 long terme pour quels patients? s\u00e9quelles des m\u00e9ningites bact\u00e9riennes chez l\u2019enfant et chez l\u2019adulte: incidence, types, modes d\u2019\u00e9valuation","volume":"39","author":"Des","year":"2009","journal-title":"Medecine et maladies infectieuses"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24004316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24004316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T19:34:47Z","timestamp":1760816087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24004316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":35,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0264410X24004316"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.04.016","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65\u00a0years-and-above in Switzerland","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}